Volpara share price leaps 5% following record cash receipts

Volpara's results appeared to impress investors today.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points
  • Volpara shares are lifting on the ASX today 
  • The health technology company reported 'record' quarterly cash receipts from customers 
  • A strategy to return to profit by FY25 was also delivered to the market 

The Volpara Health Technologies Ltd (ASX: VHT) share price is rising today after the company released its quarterly results.

The company's shares lifted 13% in earlier trade before retreating. The Volpara share price is now up 4.65%, trading at 67.5 cents.

Volpara develops software for the early detection of breast cancer. Let's take a look at what Volpara reported in today's results.

Four people on the beach leap high into the air.

Image source: Getty Images

Volpara share price responds to 'strong' update

The Q1 FY23 quarterly cash flow report is likely driving the Volpara share price higher today. Highlights include:

  • Customer cash receipts up 35% on Q1 FY22 to NZ $8.7 million
  • Net operating and investing cash outflow of NZ$3.6 million, compared to N$2.9 million in the previous quarter
  • Subscription receipts lifted 36% on prior corresponding quarter to NZ$8.3 million
  • Net cash at hand of NZ$15.2 million. A $10 million undrawn bank facility is also available
  • Guidance of NZ$31.5 to $33 million revenue in FY23

What else did Volpara report?

Volpara said cash receipts were the "strongest on record".

Net outflow was 24% on the previous quarter, due to multiple costs, including performance-related pay. Volpara was expecting this loss but plans to reduce outflows from Q3 onwards.

Volpara described its cash position as "strong" and highlighted it has no debt. Management is confident the cash at hand will help the company break even in the future.

Highlights for the quarter included a partnership with Microsoft, and a 'best scientific contribution' award for a scientific paper.

Contracted annual recurring revenue (CARR) lifted by US$1.5 million on the prior quarter to US$23.7 million.

Annual recurring revenue (ARR) also lifted by $1.2 million to US$18.5 million.

Management commentary

Speaking on the results that are giving the Volpara share price a boost today, CEO Teri Thomas said:

This quarter we are pleased with our continued growth. We are delighted about the momentum we've gained with large healthcare organisations' faith in us and our portfolio of products and services.

We are highly focused on continued support of our customers' successes, while engaging with additional 'elephant-sized' organisations for the next quarters

Strategy update

Volpara is aiming to return to profit by FY25 and balance the books by Q4 FY24. Central to this return to profit will be focussing on high revenue geographic regions, including Australia and the United States.

The company said it will prioritise sales opportunities that generate high value, and large revenue. Volpara will also keep investing in science and technology.

Commenting on this strategy, Thomas said: "This time focusing our expertise in both the products and geographical areas that provide maximum value to shareholders will position us well for growth as a profitable company within the foreseeable future."

Volpara will also freeze or limit investment in low-margin or long lead time products.

Volpara share price snapshot

The Volpara share price has lost 38% in the past year and more than 34% year to date.

However, in the past month, the company's stock has exploded 69%.

Volpara has a market capitalisation of about $173 million based on today's share price.

Motley Fool contributor Monica O'Shea has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended VOLPARA FPO NZ. The Motley Fool Australia has positions in and has recommended VOLPARA FPO NZ. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Five healthcare workers standing together and smiling.
Healthcare Shares

3 ASX 200 healthcare shares to buy amid sector rout

The experts are backing these stocks for price growth.

Read more »

Researchers and doctors with futuristic 3D hologram overlay for body anatomy or DNA in hospital clinic.
Healthcare Shares

Are investors taking a big gamble chasing 4DX shares higher and higher?

Investor interest in this ASX healthcare tech stock is booming.

Read more »

A group of people in a corporate setting do a collective high five.
Broker Notes

3 reasons to buy Ramsay Health Care shares today

A leading analyst expects Ramsay Health Care shares to keep outperforming in the months ahead.

Read more »

Half a man's face from the nose up peers over a table.
Healthcare Shares

If I could buy only 1 ASX 200 share right now, it would be…

This stock looks underpriced and oversold to me.

Read more »

woman testing substance in laboratory dish, csl share price
Healthcare Shares

CSL shares slide again in March — but is a comeback brewing?

Brokers remain upbeat and see upside up to 95% for the biotech stock.

Read more »

A female athlete in green spandex leaps from one cliff edge to another representing 3 ASX shares that are destined to rise and be great
Broker Notes

Up 57% since February, why Telix shares could keep leaping higher in 2026

A leading analyst believes investors are undervaluing Telix shares. But why?

Read more »

A woman has a thoughtful look on her face as she studies a fan of Australian 20 dollar bills she is holding on one hand while he rest her other hand on her chin in thought.
Healthcare Shares

Is it time to get greedy with CSL shares?

This ASX healthcare giant is out of favour, but that may be where opportunity starts.

Read more »

Stressed, unhappy, and tired scientist with a headache working on a computer in a lab.
Healthcare Shares

3 ASX 200 healthcare shares at multi-year lows

Does this present a buying opportunity?

Read more »